+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07315087

Safety and Early Effectiveness Study of QT-019C CAR T-cell Therapy Targeting CD19 and BCMA in Adults with Relapsed or Refractory Autoimmune Diseases

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-01-20

12

Participants Needed

1

Research Sites

2 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating universal allogeneic anti-CD19BCMA CAR T-cell therapy QT-019C in patients with relapse or refractory autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies, ANCA-associated vasculitis, connective tissue disease-associated thrombocytopenia, and SLE-ITP. This phase 1 clinical study aims to assess the safety and preliminary efficacy of this investigational treatment in these conditions where conventional therapies have failed or the disease has relapsed. Participants will receive a single intravenous infusion of QT-019C CAR T-cells following a lymphodepleting chemotherapy regimen with cyclophosphamide. The study includes one treatment arm with the investigational CAR T-cell therapy. Interim analyses will be conducted at 12 and 24 weeks after infusion to monitor responses and safety. The study is sponsored by the Institute of Hematology & Blood Diseases Hospital, China. Throughout the study, participants will be closely monitored for dose-limiting toxicities within the first 28 days and adverse events for up to 12 months after infusion. Clinical responses will be evaluated for up to 24 months. Assessments will include laboratory tests, clinical evaluations, and follow-up visits to track safety and disease activity. Participants will be followed for over two years to understand long-term effects and treatment outcomes.

CONDITIONS

Brief Title

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Research Team

Y

Ying Wang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here